The NovaLead pipeline includes multiple new pharmaceutical product opportunities, which are at various stages of development. The company expects that the time for its products to reach market would be 2 - 7 years, subject to satisfactory completion of clinical trials. It is expected that the IND for the diabetic wound will be filed in the first quarter of 2008 and for Cancer in the third quarter of 2008.
